About Our Team

Anthony Pare joined the Company in 2021.  Mr. Pare has led product development, commercialization, marketing, operations, and business development in leading medical device and diagnostic companies for 25 years. Previously, he was the Chief Commercial Officer (CCO) at T2 Biosystems, a US Nasdaq-listed in vitro diagnostics company. He held the same role at Hemanext, a pre-commercial company marketing blood transfusion technology. Mr. Pare also held various leadership roles at Haemonetics, specializing in blood processing and diagnostic technologies. He actively participates on advisory boards and mentors startup medical technology companies in the Boston (US) area. Mr. Pare holds a Bachelor of Science in Marine Engineering and a Master’s of Engineering Administration from George Washington University (US).

Other directorships: None

Neil Goldman joined the Company in 2021. Mr. Goldman previously served as the Executive Vice President and Chief Financial Officer of Chembio Diagnostics, Inc. (Nasdaq:CEMI). He has been the Executive Vice President-Corporate Development and Chief Financial Officer at J.S. Held LLC, a construction consulting firm. He was the Global Finance Director for the Delphi Data Connectivity division of Delphi Corp. (now Aptiv plc, NYSE:APTV), an automotive supplier, following Delphi’s acquisition of Unwired Technology LLC (Unwired), a tier-1 global automotive electronics manufacturer and distributor, from a private equity firm. At Unwired, he was the Executive Vice President-Corporate Development and Chief Financial Officer, the Senior Vice President-Chief Operating and Financial Officer, and previously Chief Financial Officer. He also served as the Chief Financial Officer at EPPCO Enterprises, Inc., an importer and manufacturer of consumer and aftermarket products, and as a Senior Manager at Ernst & Young LLP and its successor Cap Gemini Ernst & Young LLC. He is a Certified Public Accountant and received a Bachelor of Science degree in Business-Accountancy from Miami University (Ohio, US).

Neil is a Certified Public Accountant and received a Bachelor of Science in Business-Accountancy from Miami University (Ohio).

Nis Kruse was appointed Executive Vice President of Strategic Partnerships and General Manager of EMEA & APAC in December 2022. Most recently, Nis served as SVP & Chief Commercial Officer at SSI Diagnostica A/S, an in vitro diagnostics company focusing on infectious diseases, where he delivered substantial topline growth during the COVID pandemic. Previously, operating in a US-based position, Nis was Executive Director of Global Precision Medicine at Merck & Co. responsible for commercial diagnostic strategy and commercial partner management related to Keytruda®. Earlier in his career, he held leadership roles in Copenhagen at Agilent Technologies, H. Lundbeck, and AstraZeneca. Nis holds Master’s and Bachelor’s degrees in Economics and Business Management from Aarhus University (Denmark).

Dr. Tabari Baker was appointed Vice President of Global Medical Affairs in February 2023. Dr. Baker most recently served as Director of Strategic Healthcare Partnerships at Roche Diagnostics, where he led cross-enterprise initiatives to communicate its diagnostic portfolio’s medical value throughout the patient journey. Also at Roche, Dr. Baker supported the launch of multiple companion diagnostic tests by providing clinical, scientific, and educational expertise as a Scientific Affairs Manager. Previously, Dr. Baker served in research and clinical liaison roles at Caris Life Sciences. Dr. Baker received his Ph.D. in Tumor Biology from Georgetown University. He earned an M.S. in Cancer Biology, Prevention, and Control from the University of the District of Columbia, and a B.S. in Chemistry from Morehouse College. 

Asger was appointed Vice President of Quality Assurance and Regulatory Affairs at BioPorto in October 2021. With more than 20 years in the medical industry and a key focus on quality management. Asger provides a proven track record in the management of global quality organizations, strategic thinking, and execution. While at Agilent Technologies, Asger managed a team of 45 to provide ongoing quality support including management reviews, and audits (FDA, notifying bodies, internal and vendor). His experience also includes managing and supporting major IT implementations and a new IVD-R system for Complaints, Vigilance, NCR, and Post Market Surveillance. Asger holds a Bachelor of Science in Engineering from the DTU-Technical University of Denmark.

Ursula was appointed Vice President of Research and Development in December 2020. In this function, she leads a team of highly qualified and motivated scientists who are passionate about providing superior products to improve patients’ lives. She has a strong scientific background with more than 15 years in assay development and validation, system integration, biomarker discovery, and new technology assessments. Most recently, she served as a Senior Scientific Affairs Manager at Roche Diagnostics, where she managed and led industry-supported and industry-sponsored studies and served as point-of-contact for all customer off-label questions in regard to assays quality, standardization, and clinical utility. Ursula has a Master’s degree in Nutritional Sciences from the University of Bonn (Germany), and a PhD in Molecular Biology from the University of Cologne (Germany).

Jennifer excels at leading sales organizations through change such as growth, new markets, product launches and team integrations. Focusing on process and system improvements and developing methods and teams to consistently achieve revenue goals is the key to her success. Jennifer’s sales career has spanned both medical and high tech; she has a Masters Certificate from Wayne State and a Bachelor of Science from Alma College.

With over 39 years of medical experience, Dr. Prasad Devarajan, MD, FAAP, FASN, joined the BioPorto team as Senior Medical Director in July 2022. He is a world-renown pediatric nephrologist at Cincinnati Children’s Hospital Medical Center in Ohio, where he is the Director of the Nephrology and Hypertension Division, Medical Director of the Stone Center, and Professor at the UC Department of Pediatrics. In addition, Dr. Devarajan is on the editorial and review boards of more than 20 journals and multiple US National Institutes of Health (NIH) study sections. He has authored more than 320 peer-reviewed journal articles, and his work has been continuously funded by NIH and several other foundations for over 30 years. He graduated from Lokmanya Tilak Municipal Medical College medical school.